Rusalatide acetate is under clinical development by Chrysalis BioTherapeutics and currently in Phase II for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). According to GlobalData, Phase II drugs for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rusalatide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rusalatide acetate overview
Rusalatide acetate (Chrysalin, TP-508) is under development for the treatment of acute respiratory distress syndrome (ARDS) or lung injury, and myocardial ischemia, radiation exposure, diabetic foot ulcers, traumatic brain injury, neurodegenerative disease, brain cancer, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thrombosis and systemic vascular damage caused by SARS-CoV-2 infection. Chrysalin is administered topically and parenterally as a powder. Chrysalin (TP-508) is a 23-amino acid synthetic peptide. Chrysalin represents a receptor-binding domain of the human thrombin molecule, a naturally occurring molecule in the body responsible for both blood clotting and initiating many of the cellular events responsible for tissue repair. Chrysalin mimics specific attributes of the thrombin molecule. It has the potential to accelerate the natural cascade of healing events. The drug candidate was also under development for the treatment of fracture, myocardial infarction, ischemia, orthopedic tissue repair, neural regeneration, restenosis and vascular endothelial diseases, burns.
Chrysalis BioTherapeutics overview
Chrysalis BioTherapeutics (Chrysalis), is a biopharmaceutical company that develops and commercializes drugs. It uses natural peptide regenerative drugs to restore vascular function and activate normal stem cell populations where they exist in the body. The company’s lead product Chrysalin (TP508) which treats acute respiratory distress syndrome (ARDS), pulmonary fibrosis, radiation therapy, traumatic brain injury. TP508 also activates a signaling cascade that restores vascular function in endothelial cells, stimulates proliferation and mobilization of progenitor stem cells, and reduces inflammation. Chrysalis is headquartered in Galveston, Texas, the US.
For a complete picture of Rusalatide acetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
